Inhibition of indoleamine-2,3-dioxygenase (IDO) in glioblastoma cells by oncolytic herpes simplex virus

Advances in Virology

Volumn 2012, Issue , 2012, Pages

  Reinhart, Bonnie ^a   Mazzacurati, Lucia ^b   Forero, Adriana ^a   Hong, Chang Sook ^a   Eguchi, Junichi ^a   Okada, Hideho ^a   Fellows, Wendy ^a   Niranjan, Ajay ^a   Cohen, Justus B ^a   Glorioso, Joseph C ^a   Grandi, Paola ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPESVIRIDAE; SIMPLEXVIRUS;

EID: 84873841784     PISSN: 16878639     EISSN: 16878647     Source Type: Journal    
DOI: 10.1155/2012/815465     Document Type: Article

References (45)

1. Grandi P., Peruzzi P., Reinhart B., Cohen J. B., Chiocca E. A., Glorioso J. C., Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Review of Neurotherapeutics 2009 9 4 505 517 2-s2.0-66249120034 10.1586/ern.09.9
2. Hu J. C., Booth M. J., Tripuraneni G., Davies D., Zaidi S. A. A., De Bella M. T., Slade M. J., Marley S. B., Gordon M. Y. A., Coffin R. S., Coombes R. C., Kamalati T., A novel HSV-1 virus, JS1/34.5-/47-purges contaminating breast cancer cells from bone marrow. Clinical Cancer Research 2006 12 22 6853 6862 2-s2.0-33845303948 10.1158/1078-0432.CCR-06-1228 (Pubitemid 44876856)
3. Markert J. M., Medlock M. D., Rabkin S. D., Gillespie G. Y., Todo T., Hunter W. D., Palmer C. A., Feigenbaum F., Tornatore C., Tufaro F., Martuza R. L., Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000 7 10 867 874 2-s2.0-12944315014 (Pubitemid 30303584)
4. Papanastassiou V., Rampling R., Fraser M., Petty R., Hadley D., Nicoll J., Harland J., Mabbs R., Brown M., The potential for efficacy of the modified (ICP 34.5-) herpes simplex virus HSV1716 following intratumoural injection into malignant glioma: a proof of principle study. Gene Therapy 2002 9 6 398 406 2-s2.0-0036228985 10.1038/sj/gt/3301664 (Pubitemid 34414038)
5. Rampling R., Cruickshank G., Papanastassiou V., Nicoll J., Hadley D., Brennan D., Petty R., MacLean A., Harland J., McKie E., Mabbs R., Brown M., Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 2000 7 10 859 866 2-s2.0-12944272092 (Pubitemid 30303583)
6. Senzer N. N., Kaufman H. L., Amatruda T., Nemunaitis M., Reid T., Daniels G., Gonzalez R., Glaspy J., Whitman E., Harrington K., Goldsweig H., Marshall T., Love C., Coffin R., Nemunaitis J. J., Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. Journal of Clinical Oncology 2009 27 34 5763 5771 2-s2.0-73349133717 10.1200/JCO.2009.24.3675
7. Everett R. D., Orr A., Herpes simplex virus type 1 regulatory protein ICP0 aids infection in cells with a preinduced interferon response but does not impede interferon-induced gene induction. Journal of Virology 2009 83 10 4978 4983 2-s2.0-65349141759 10.1128/JVI.02595-08
8. Halford W. P., Weisend C., Grace J., Soboleski M., Carr D. J. J., Balliet J. W., Imai Y., Margolis T. P., Gebhardt B. M., ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virology Journal 2006 3, article 44 2-s2.0-33748356480 10.1186/1743-422X-3-44 (Pubitemid 44336808)
9. Leib D. A., Harrison T. E., Laslo K. M., Machalek M. A., Moorman N. J., Virgin H. W., Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. Journal of Experimental Medicine 1999 189 4 663 672 2-s2.0-0033557288 10.1084/jem.189.4.663 (Pubitemid 29193367)
10. Gu H., Roizman B., Herpes simplex virus-infected cell protein 0 blocks the silencing of viral DNA by dissociating histone deacetylases from the CoREST-REST complex. Proceedings of the National Academy of Sciences of the United States of America 2007 104 43 17134 17139 2-s2.0-36749032258 10.1073/pnas.0707266104 (Pubitemid 350211004)
11. Cai W., Schaffer P. A., Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells. Journal of Virology 1992 66 5 2904 2915 2-s2.0-0026533363
12. Chen J., Silverstein S., Herpes simplex viruses with mutations in the gene encoding ICP0 are defective in gene expression. Journal of Virology 1992 66 5 2916 2927 2-s2.0-0026528539
13. Boutell C., Everett R., Hilliard J., Schaffer P., Orr A., Davido D., Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner. Journal of Virology 2008 82 21 10647 10656 2-s2.0-55249088121 10.1128/JVI.01063-08 (Pubitemid 352691194)
14. Boutell C., Orr A., Everett R. D., PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0. Journal of Virology 2003 77 16 8686 8694 2-s2.0-0042709466 10.1128/JVI.77.16.8686-8694.2003 (Pubitemid 36936079)
15. Boutell C., Sadis S., Everett R. D., Herpes simplex virus type 1 immediate-early protein ICP0 and its isolated RING finger domain act as ubiquitin E3 ligases in vitro. Journal of Virology 2002 76 2 841 850 2-s2.0-0036138854 10.1128/JVI.76.2.841-850.2002 (Pubitemid 34033381)
16. Chelbi-Alix M. K., De Thé H., Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 1999 18 4 935 941 2-s2.0-0033611590 10.1038/sj.onc.1202366 (Pubitemid 29086270)
17. Everett R. D., Herpes simplex virus type 1 regulatory protein ICP0 does not protect cyclins D1 and D3 from degradation during infection. Journal of Virology 2004 78 18 9599 9604 2-s2.0-4444329792 10.1128/JVI.78.18.9599-9604.2004 (Pubitemid 39187077)
18. Lin R., Noyce R. S., Collins S. E., Everett R. D., Mossman K. L., The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes. Journal of Virology 2004 78 4 1675 1684 2-s2.0-0842326034 10.1128/JVI.78.4.1675-1684.2004 (Pubitemid 38176700)
19. Lomonte P., Sullivan K. F., Everett R. D., Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0. Journal of Biological Chemistry 2001 276 8 5829 5835 2-s2.0-0035937114 10.1074/jbc.M008547200
20. Stow N. D., Stow E. C., Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110. Journal of General Virology 1986 67 12 2571 2585 2-s2.0-0022978685 (Pubitemid 17197588)
21. Sacks W. R., Schaffer P. A., Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture. Journal of Virology 1987 61 3 829 839 2-s2.0-0023135555 (Pubitemid 17040212)
22. Yao F., Schaffer P. A., An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. Journal of Virology 1995 69 10 6249 6258 2-s2.0-0029102140
23. Sobol P. T., Hummel J. L., Rodrigues R. M., Mossman K. L., PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses. Gene Therapy 2009 16 9 1077 1087 2-s2.0-70249130819 10.1038/gt.2009.68
24. Hummel J. L., Safroneeva E., Mossman K. L., The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Molecular Therapy 2005 12 6 1101 1110 2-s2.0-28444480639 10.1016/j.ymthe.2005.07.533 (Pubitemid 41723044)
25. Fulci G., Breymann L., Gianni D., Kurozomi K., Rhee S. S., Yu J., Kaur B., Louis D. N., Weissleder R., Caligiuri M. A., Chiocca E. A., Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proceedings of the National Academy of Sciences of the United States of America 2006 103 34 12873 12878 2-s2.0-33748088164 10.1073/pnas.0605496103 (Pubitemid 44298654)
26. Friedman A., Tian J. P., Fulci G., Chiocca E. A., Wang J., Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Research 2006 66 4 2314 2319 2-s2.0-33644547005 10.1158/0008-5472.CAN-05-2661
27. Adams O., Besken K., Oberdörfer C., MacKenzie C. R., Rüßing D., Däubener W., Inhibition of human herpes simplex virus type 2 by interferon γ and tumor necrosis factor α is mediated by indoleamine 2,3-dioxygenase. Microbes and Infection 2004 6 9 806 812 2-s2.0-3242683496 10.1016/j.micinf.2004.04.007
28. Munn D. H., Mellor A. L., Indoleamine 2,3-dioxygenase and tumor-induced tolerance. Journal of Clinical Investigation 2007 117 5 1147 1154 2-s2.0-34248173331 10.1172/JCI31178 (Pubitemid 46718399)
29. Zamanakou M., Germenis A. E., Karanikas V., Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunology Letters 2007 111 2 69 75 2-s2.0-34547663303 10.1016/j.imlet.2007.06.001 (Pubitemid 47212491)
30. Katz J. B., Muller A. J., Prendergast G. C., Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunological Reviews 2008 222 1 206 221 2-s2.0-41149132390 10.1111/j.1600-065X.2008.00610.x (Pubitemid 351430372)
31. Hong C. S., Fellows W., Niranjan A., Alber S., Watkins S., Cohen J. B., Glorioso J. C., Grandi P., Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Therapy 2010 17 10 1200 1205 2-s2.0-77958001733 10.1038/gt.2010.66
32. Tyminski E., LeRoy S., Terada K., Finkelstein D. M., Hyatt J. L., Danks M. K., Potter P. M., Saeki Y., Chiocca E. A., Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Research 2005 65 15 6850 6857 2-s2.0-23044450359 10.1158/0008-5472.CAN-05-0154 (Pubitemid 41060724)
33. Markert J. M., Liechty P. G., Wang W., Gaston S., Braz E., Karrasch M., Nabors L. B., Markiewicz M., Lakeman A. D., Palmer C. A., Parker J. N., Whitley R. J., Gillespie G. Y., Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Molecular Therapy 2009 17 1 199 207 2-s2.0-58149237728 10.1038/mt.2008.228
34. Markert J. M., Parker J. N., Buchsbaum D. J., Grizzle W. E., Gillespie G. Y., Whitley R. J., Oncolytic HSV-1 for the treatment of brain tumours. Herpes 2006 13 3 66 71 2-s2.0-33845674106 (Pubitemid 44955374)
35. Mineta T., Rabkin S. D., Yazaki T., Hunter W. D., Martuza R. L., Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Medicine 1995 1 9 938 943 2-s2.0-0029023868
36. Mossman K. L., Smiley J. R., Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication. Journal of Virology 2002 76 4 1995 1998 2-s2.0-0036150004 10.1128/JVI.76.4.1995-1998.2002 (Pubitemid 34094647)
37. Sacks W. R., Schaffer P. A., Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture. Journal of Virology 1987 61 3 829 839 2-s2.0-0023135555 (Pubitemid 17040212)
38. Jenkins F. J., Roizman B., Herpes simplex virus 1 recombinants with noninverting genomes frozen in different isomeric arrangements are capable of independent replication. Journal of Virology 1986 59 2 494 499 2-s2.0-0022504772 (Pubitemid 16014000)
39. Prestwich R. J., Errington F., Diaz R. M., Pandha H. S., Harrington K. J., Melcher A. A., Vile R. G., The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Human gene therapy 2009 20 10 1119 1132 2-s2.0-70450200778
40. Miyazaki T., Moritake K., Yamada K., Hara N., Osago H., Shibata T., Akiyama Y., Tsuchiya M., Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy: laboratory investigation. Journal of Neurosurgery 2009 111 2 230 237 2-s2.0-68849112548 10.3171/2008.10.JNS081141
41. Guillemin G. J., Cullen K. M., Lim C. K., Smythe G. A., Garner B., Kapoor V., Takikawa O., Brew B. J., Characterization of the kynurenine pathway in human neurons. Journal of Neuroscience 2007 27 47 12884 12892 2-s2.0-36448939072 10.1523/JNEUROSCI.4101-07.2007 (Pubitemid 350161746)
42. Okano F., Storkus W. J., Chambers W. H., Pollack I. F., Okada H., Identification of a novel HLA-A 0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clinical Cancer Research 2002 8 2851 2855 2-s2.0-33745199108 10.1158/1078-0432.CCR-12-11-COR (Pubitemid 35025729)
43. Alvira M. R., Goins W. F., Cohen J. B., Glorioso J. C., Genetic studies exposing the splicing events involved in herpes simplex virus type 1 latency-associated transcript production during lytic and latent infection. Journal of Virology 1999 73 5 3866 3876 2-s2.0-0032958432 (Pubitemid 29189830)
44. Tsvitov M., Frampton A. R., Shah W. A., Wendell S. K., Ozuer A., Kapacee Z., Goins W. F., Cohen J. B., Glorioso J. C., Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology 2007 360 2 477 491 2-s2.0-33947572905 10.1016/j.virol.2006.10.039 (Pubitemid 46482613)
45. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001 25 4 402 408 2-s2.0-0035710746 10.1006/meth.2001.1262 (Pubitemid 34164012)